- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Jay Berfas
Jay Berfas, Publisher
T: (212) 951-6614
jberfas@advanstar.com
Jay Berfas joined Advanstar Communications in September 2006 as Group Publisher of Pharmaceutical Executive and Pharmaceutical Representative Magazines. In this role, Jay is responsible for the overall business and strategic development of print and electronic media products for the Group. Jay brings to Advanstar over 30 years of publishing and senior management experience. Previously, Jay held posts as Vice President for Institutional Investor magazine, where he spent 14 years in management positions and Global Finance, where he headed worldwide advertising sales as Associate Publisher from 1992-2000. Until October 2005, Jay was Group Publisher of SourceMedia's Banking Magazines Group, where he managed the Group's editorial and business operations, launched several successful e-newsletters, and helped create a successful Webcast business. Jay has a MA from New York University and earned a Bachelor of Arts with honors from Queens College of the City University of New York.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
